Research
Landmark findings, honest summaries — the plain-English finding, why it matters, and the catch.
Only landmark work that moved the field — with the context headlines skip: sample size, funding, replication.
The US federal stance softens 2026
In April 2026, a presidential executive order directed federal agencies to speed up the research, review, and approval process for psychedelics as treatments for serious mental illness, including faster FDA review and new research funding.
Why it matters — a sitting US president putting real weight behind these substances is without precedent — a genuine signal after fifty years of federal prohibition.
The catch
It approves nothing and legalizes nothing. The drugs stay Schedule I — this is funding and direction for research and faster review, not access. Easy to mistake for legalization. It isn't.
MDMA for PTSD — and the wall it hit 2024
Two late-stage trials showed some of the strongest PTSD improvements ever recorded for MDMA-assisted therapy versus placebo. Then, in 2024, the FDA declined to approve it.
Why it matters — MDMA was the field’s frontrunner, the treatment most likely to become the first legal psychedelic medicine in the US. Its rejection reset the timeline for everyone and forced the whole field to raise its standards.
The catch
An FDA advisory panel voted overwhelmingly against it, and the agency asked for another trial. Reviewers flagged how the studies were run, the fact that people could usually tell they got MDMA, and gaps in safety reporting — and several related papers were retracted. Strong results aren't the same as approval. This is the clearest proof of that.
Australia goes first 2023
On 1 July 2023, Australia became the first country to let authorised psychiatrists prescribe MDMA for PTSD and psilocybin for treatment-resistant depression — moving them out of the “prohibited” category for medical use.
Why it matters — it’s the first time any national government opened a legal prescription path for these substances. Everyone watching psychedelic policy is watching how it plays out.
The catch
It's narrow: authorised psychiatrists only, just those two conditions, and in practice it's been expensive and slow to reach people. This is regulated medical access, not legalization.
The US states leading the federal government 2023
Oregon launched the country’s first regulated psilocybin services in 2023, where adults can take psilocybin with a trained facilitator at a licensed center. Colorado followed with its own voter-approved program, opening licensing at the end of 2024.
Why it matters — this is where supervised, legal psychedelic access actually exists in the US right now — running years ahead of anything at the federal level.
The catch
State-legal is not federally legal. Access is supervised-only at licensed centers, and both rollouts have been slow and expensive. A real door, but a narrow and costly one.
Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs. Placebo in the Treatment of Adult Patients With Alcohol Use Disorder 2022
Summary
A randomized trial of 93 participants with alcohol use disorder compared two doses of psilocybin plus psychotherapy to an active placebo (diphenhydramine/Benadryl) plus psychotherapy.
At 8 months following the first dose, participants in the psilocybin group had significantly fewer heavy drinking days (9.7% vs. 23.6%). Percentage of abstinent days was also higher in the psilocybin group.
Honest Limitations
- The active control (diphenhydramine) produced noticeable sedation, but participants may still have correctly guessed their assignment
- Sample size modest
- No long-term follow-up beyond 8 months published at time of initial analysis
- Psychotherapy was extensive and specialized
- Alcohol use disorder is a relapsing condition; durability remains a key question
Why It Matters
Building on the smoking cessation pilot, this trial extended psychedelic therapy to alcohol use disorder — a massive public health problem with few effective treatments. The results were promising enough to support ongoing phase 3 development.
The biggest psilocybin trial yet — and a more honest number 2022
The largest controlled psilocybin study to date — 233 people across ten countries — tested a single 25mg dose with psychological support against lower doses. The high dose produced a statistically significant drop in depression at three weeks.
Why it matters — this is the program furthest along toward becoming an actual approved medicine, and the first to carry psilocybin into Phase 3 trials.
The catch
About 37% responded at three weeks on the high dose — real, but lower than first-line antidepressants manage in some trials, and a chunk relapsed. There were also some serious adverse events. The grown-up data, not the miracle headline.
Psilocybin versus Escitalopram for Depression 2021
Summary
A head-to-head trial compared two doses of psilocybin plus specialized psychotherapy to a 6-week course of escitalopram (Lexapro) plus placebo in 59 participants with moderate-to-severe depression.
On the primary endpoint (change in depression score at week 6), there was no statistically significant difference between psilocybin and escitalopram. However, on several secondary measures — including response rates, remission rates, and wellbeing scores — psilocybin showed numerically superior results.
Honest Limitations
- Small sample size (59 participants)
- The primary endpoint did not reach statistical significance, which is the standard regulatory benchmark
- The psychotherapy provided alongside psilocybin was extensive and specialized, making it hard to isolate the drug effect
- The escitalopram group received daily placebo capsules, while the psilocybin group received active therapy on dosing days — the control conditions were not perfectly matched
Why It Matters
This trial was methodologically ambitious and headline-grabbing, but its mixed results are arguably more informative than clear-cut success would have been. It suggests psilocybin may be at least as effective as a standard SSRI, but it also shows the challenges of designing fair comparison trials in psychedelic research. The field learned enormously from this study’s design challenges.
Psilocybin for depression — the trials that restarted the field 2020
A single high dose of psilocybin, paired with therapy, produced large and fast drops in depression — with most participants still improved a month later. In this trial the effect ran several times larger than what standard antidepressants typically show.
Why it matters — this is the proof-of-concept the entire modern psychedelic field is built on. Nearly everything that followed traces back to results like these.
The catch
The sample was tiny — 24 people — and you can't truly blind a psychedelic trial, because people know whether they got the drug. That inflates the effect. A landmark, but an early, small one.
Psilocybin Produces Substantial and Sustained Decreases in Depression and Anxiety in Patients with Life-Threatening Cancer 2016
Summary
A randomized trial of 51 cancer patients with clinically significant anxiety or depression found that a single high dose of psilocybin produced rapid, substantial, and sustained decreases in psychological distress.
At 5 weeks, 80% of participants in the psilocybin group showed clinically significant reductions in depression and anxiety. At 6 months, these benefits largely persisted. Participants also reported increases in quality of life, life meaning, and optimism.
Honest Limitations
- Crossover design means all participants eventually received psilocybin, limiting long-term between-group comparison
- Small sample
- The existential nature of cancer-related distress may respond differently than general depression
- High-rate of mystical-type experiences reported, which may correlate with outcomes but doesn’t explain mechanism
Why It Matters
This study helped establish the therapeutic legitimacy of psilocybin in one of the most emotionally resonant possible indications: helping people facing mortality find peace. The sustained effects from a single dose were remarkable and helped shift public and scientific opinion.
Psilocybin-Assisted Therapy for Smoking Cessation: A Pilot Study 2014
Summary
An open-label pilot study of 15 cigarette smokers found that a structured psilocybin-assisted therapy program produced 80% abstinence at 6 months — a rate far exceeding typical pharmacological treatments for smoking (which usually achieve 20–35% abstinence).
Participants received preparation therapy, two or three psilocybin sessions, and cognitive-behavioral therapy. Abstinence was biochemically verified.
Honest Limitations
- Open-label (no placebo control)
- Very small sample (15 participants)
- Self-selected, highly motivated smokers
- No comparison to CBT alone or other active treatments
- Long-term durability beyond 12 months less well-established
Why It Matters
Smoking cessation is a notoriously difficult target for any intervention. The effect size here was striking enough to warrant larger trials. It also opened the door to considering psychedelics for addiction more broadly — a direction now being explored for alcohol use disorder and opioid addiction.
Psychedelics and Mental Health: A Population Study 2013
Summary
An analysis of data from over 130,000 US adults found no significant association between lifetime psychedelic use and increased rates of mental health problems. In several cases, psychedelic use was associated with lower rates of psychological distress, suicidal ideation, and inpatient mental health treatment.
The study used data from the National Survey on Drug Use and Health (NSDUH), a large representative sample.
Honest Limitations
- Cross-sectional observational data cannot establish causation
- People who use psychedelics may differ systematically from those who don’t (healthy user bias)
- Retrospective self-report of both psychedelic use and mental health outcomes
- Doesn’t capture acute risks or rare adverse events
Why It Matters
This study challenged the lingering cultural assumption that psychedelic use inevitably damages mental health. It didn’t prove psychedelics are universally safe — it couldn’t, given its design — but it did show that, at a population level, the dire warnings of the anti-drug era were not supported by data.
Psilocybin Treatment of Obsessive-Compulsive Disorder 2006
Summary
A small open-label study of 9 participants with treatment-resistant OCD found that psilocybin produced substantial symptom reductions in most participants. Symptoms decreased rapidly and, in some cases, remained reduced for over 24 hours from a single dose.
Honest Limitations
- Extremely small sample (9 participants)
- Open-label with no control group
- OCD symptoms naturally wax and wane, making interpretation difficult without controls
- No replication studies as of 2024–2025
Why It Matters
This study is rarely cited in mainstream psychedelic coverage, but it’s notable for targeting a condition (OCD) that is severely impairing and often treatment-resistant. The lack of follow-up research illustrates both the funding challenges of psychedelic science during the prohibition era and the need for replication across all claimed indications.